Literature DB >> 12564733

Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997).

Kim P Freeman1, Kevin A Hahn, F Dee Harris, Glen K King.   

Abstract

This retrospective study in 39 dogs with incompletely resected oral melanoma examined the efficacy of hypofractionated radiation therapy and platinum-containing chemotherapy. All dogs were completely staged, with the majority of dogs classified as stage 1. Dogs received 6 weekly fractions of 6-gray (Gy) megavoltage irradiation with a cobalt-60 unit or a 4-MeV (megaelectron volts) linear accelerator. Dogs received cisplatin (10-30 mg/m2 IV) or carboplatin (90 mg/m2 IV) chemotherapy 60 minutes before radiation delivery. Durations of local control, metastasis-free survival time, and overall survival time were recorded. By the Kaplan-Meier method, 15% of the dogs had local recurrence within a median time of 139 days. Fifty-one percent of the dogs developed metastatic disease within a median time of 311 days (range, 24-2, 163 days). Median survival time for all 39 dogs was 363 days. The combined use of chemotherapy and radiation therapy in this protocol provided local control consistent with previous studies. Low-dose chemotherapy was used with the intent of enhancing radiation therapy for the local control of an incompletely excised tumor. Survival times were longer than previously reported for dogs with oral malignant melanoma. Additional studies are required to determine whether these results were due to the effects of chemotherapy on microscopic disease or the enhanced local control provided by chemoradiation therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12564733     DOI: 10.1892/0891-6640(2003)017<0096:todwom>2.3.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  22 in total

1.  Low-dose pretreatment for radiation therapy.

Authors:  Richard Blankenbecler
Journal:  Dose Response       Date:  2010-09-10       Impact factor: 2.658

2.  Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas.

Authors:  Tarso Felipe Teixeira; Luciana Boffoni Gentile; Tereza Cristina da Silva; Gregory Mennecier; Lucas Martins Chaible; Bruno Cogliati; Marco Antonio Leon Roman; Marco Antonio Gioso; Maria Lucia Zaidan Dagli
Journal:  Vet Res Commun       Date:  2013-10-15       Impact factor: 2.459

3.  Bilateral phalangeal fillet technique for metacarpal pad reconstruction in a dog.

Authors:  Tania Shaw; Fleur James; Lucas Beierer; Giselle Hosgood
Journal:  Can Vet J       Date:  2014-10       Impact factor: 1.008

4.  6-Bromoindirubin-3'oxime (BIO) decreases proliferation and migration of canine melanoma cell lines.

Authors:  Esther Chon; Brandi Flanagan; Lucas Campos de Sá Rodrigues; Caroline Piskun; Timothy J Stein
Journal:  Vet J       Date:  2014-07-31       Impact factor: 2.688

5.  Clinical systemic lupeol administration for canine oral malignant melanoma.

Authors:  Inoru Yokoe; Kazuo Azuma; Keishi Hata; Toshiyuki Mukaiyama; Takahiro Goto; Takeshi Tsuka; Tomohiro Imagawa; Norihiko Itoh; Yusuke Murahata; Tomohiro Osaki; Saburo Minami; Yoshiharu Okamoto
Journal:  Mol Clin Oncol       Date:  2014-10-30

Review 6.  Treatment of Canine Oral Melanomas: A Critical Review of the Literature.

Authors:  Paolo Pazzi; Gerhard Steenkamp; Anouska J Rixon
Journal:  Vet Sci       Date:  2022-04-19

7.  Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: A retrospective study on 68 cases (2010-2020).

Authors:  Mariateresa Camerino; Davide Giacobino; Luca Manassero; Selina Iussich; Federica Riccardo; Federica Cavallo; Lidia Tarone; Matteo Olimpo; Elena Lardone; Marina Martano; Sara Del Magno; Paolo Buracco; Emanuela Morello
Journal:  Vet Comp Oncol       Date:  2021-09-06       Impact factor: 2.385

8.  Activation of the canonical Wnt/β-catenin signalling pathway is rare in canine malignant melanoma tissue and cell lines.

Authors:  E Chon; V Thompson; S Schmid; T J Stein
Journal:  J Comp Pathol       Date:  2012-08-14       Impact factor: 1.311

9.  Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases.

Authors:  Davide Giacobino; Mariateresa Camerino; Federica Riccardo; Federica Cavallo; Lidia Tarone; Marina Martano; Alfredo Dentini; Selina Iussich; Elena Lardone; Paolo Franci; Alberto Valazza; Luca Manassero; Sara Del Magno; Raffaella De Maria; Emanuela Morello; Paolo Buracco
Journal:  Vet Comp Oncol       Date:  2021-03-22       Impact factor: 2.385

10.  Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.

Authors:  L A Piras; F Riccardo; S Iussich; L Maniscalco; F Gattino; M Martano; E Morello; S Lorda Mayayo; V Rolih; F Garavaglia; R De Maria; E Lardone; F Collivignarelli; D Mignacca; D Giacobino; S Ferrone; F Cavallo; P Buracco
Journal:  Vet Comp Oncol       Date:  2016-05-04       Impact factor: 2.613

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.